CROI 2019 Program and Conference Information

Oral Sessions

Conveners Vicente Planelles, University of Utah School of Medicine, Salt Lake City, UT, USA Florence Margottin-Goguet, Institut Cochin, INSERM, Paris, France 108

THE CURRENT STATUS OF LATENCY REVERSING AGENTS Carine M. Van Lint, Université Libre de Bruxelles, Brussels, Belgium DISCOVERY AND CHARACTERIZATION OF A VIRUS- INTRINSIC HIV LATENCY CIRCUIT Leor Weinberger, Gladstone Institutes, San Francisco, CA, USA SILENCING OF RETROVIRAL GENE EXPRESSION BY THE HUSH COMPLEX Stephen P. Goff, Columbia University Medical Center, New York, NY, USA THE POWER OF THE HIV PROMOTER: IMPACT OF HIV-DRIVENVIRAL AND HOST GENE EXPRESSION Ya-Chi Ho, Yale University, New Haven, CT, USA

4:00

109 4:30

110 5:00

111 5:30

Symposium S-5 COINFECTIONS: TUBERCULOSIS, HEPATITIS B AND C, AND HIV Room 6E 4:00 PM - 6:00 PM Target Audience: This session is directed to persons interested in understanding the importance of tuberculosis and hepatitis confections in persons with HIV. Level of Knowledge: It is assumed that the audience has a broad knowledge of medicine and infectious diseases. Objectives: After attending this session, learners will be able to: • Outline the journey to HBV cure • Describe HCV vaccine development and recent trial results • Describe recent advances in treating and preventing tuberculosis Conveners Lele Rangaka, University College London, London, United Kingdom Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand 112 DYNAMICS OF ACUTE HCV INWESTERN EUROPE Jürgen K. Rockstroh, University of Bonn, Bonn, Germany CME 4:00

Oral Sessions • Wednesday

113 4:30

A VACCINE TO PREVENT HCV: AREWE GETTING THERE? Andrea L. Cox, Johns Hopkins University, Baltimore, MD, USA CHOICES AND DILEMMAS: PREVENTING TUBERCULOSIS IN PEOPLEWITHHIV INFECTION Amita Gupta, Johns Hopkins University, Baltimore, MD, USA

114 5:00

CROI 2019 51